Goldman Sachs Added Teva Pharmaceutical (TEVA) to its Conviction Buy List
More News related to TEVA
- Teva (TEVA) and Barr (BRL) Receive FTC Second Request Regarding Pending Acqusition
- Teva and Barr Receive FTC Request for Additional Information
- Teva and Barr Receive FTC Request for Additional Information
- Analyst Reports for Electronic Arts Inc., Teva Pharmaceutical Industries Limited, ACADIA Pharmaceuticals Inc., and Sport Supply Group Inc.
- Group Acquires IVAX Diagnostics (IVD) Shares From Teva Pharmaceutical (TEVA) for $14 Million
More News related to Analyst Comments
- Citi Reiterates 'Buy' on Estee Lauder (EL), Raises Price Target After Impressive Meeting with CEO
- Deutsche Bank Lowers Rating On UST Inc (UST) From Buy To Hold
- Apple (AAPL) Event Could Be Disappointment -AmTech
- Goldman Sachs Removed EOG Resources (EOG) from its Conviction Buy List
- Goldman Sachs Removed ConocoPhillips (COP) from its Conviction Buy List
Goldman Sachs added Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) to its Conviction Buy List.
Teva Pharmaceutical Industries Limited develops, manufactures, and markets generic and human pharmaceuticals, as well as active pharmaceutical ingredients.
Shares of TEVA fell 8.5% yesterday following disappointing data on 40mg dosage strength of Copaxone.
Related Categories
Analyst CommentsStocks Mentioned
-0.36Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
